Key facts
- Azra AI’s last known valuation is $235.0M (Jan 2026).
- It has raised $18.9M; the latest was Later Stage VC ($11.0M) in Jan 2026.
- Notable investors include SJF Ventures, FCA Venture Partners, NewHealth Ventures, Sopris Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Azra AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Azra AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Azra AI
Developer of an AI-powered platform designed to automate workflows and coordinate care across oncology and critical service lines. The company offers real-time analysis of pathology and radiology reports, ADT feeds, and clinical data, enabling hospitals to identify patients earlier, connect them to coordinated care faster, and manage treatment journeys more efficiently.
- Sector
- Healthcare
- HQ
- Nashville, TN, United States
- Founded
- 2021
- Employees
- 42
- Website
- azra-ai.com/
- Ownership
- Privately Held (backing)
Azra AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Azra AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Azra AI in its N-PORT filings yet. We sweep new filings monthly.